Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.
Weill Cornell Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners
Latest from Weill Cornell Sandra & Edward Meyer Cancer Center
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Advertisement
Advertisement
Trending on CURE
1
Body Image and Sexual Health Challenges After Breast Cancer
2
Breast Cancer Awareness Needs Action, Not Just Pink Ribbons
3
What Libtayo Means for High-Risk Cutaneous Squamous Cell Carcinoma
4
FDA Grants Fast Tract Designation to VT3989 for Mesothelioma
5
